A Multi-site, Open-label, Sequential-group, Multiple-dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
Latest Information Update: 25 Sep 2025
At a glance
- Drugs Lu AG13909 (Primary)
- Indications Congenital adrenal hyperplasia
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Lundbeck A/S
Most Recent Events
- 10 Sep 2025 Planned End Date changed from 1 Feb 2028 to 31 Dec 2027.
- 10 Sep 2025 Planned primary completion date changed from 1 Sep 2026 to 30 Sep 2026.
- 18 Aug 2025 Planned number of patients changed from 46 to 57.